Related Experiment Videos
Juvenile dermatomyositis in north India
S Singh1, L Kumar, K R Shankar
1Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh.
Indian Pediatrics
|March 1, 1997
Summary
Juvenile dermatomyositis (JDM) patients typically respond well to early corticosteroid therapy. Methotrexate is an option for children with JDM who show limited improvement with prolonged steroid treatment.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Dermatology
Background:
- Juvenile dermatomyositis (JDM) is a rare autoimmune disease affecting children.
- Understanding its clinical presentation and treatment outcomes is crucial for effective management.
Purpose of the Study:
- To characterize the clinical profile of JDM patients.
- To evaluate the therapeutic response to treatments in JDM.
Main Methods:
- A hospital-based descriptive follow-up study was conducted.
- Data from 12 pediatric patients diagnosed with JDM over five years were analyzed.
Main Results:
- Proximal muscle weakness was a universal finding in JDM patients.
- Skin manifestations were common, while muscle pain and vasculitis were infrequent.
- Early corticosteroid therapy (prednisolone) led to excellent clinical responses in most JDM cases.
- Two patients with refractory disease showed improvement with methotrexate.
Conclusions:
- Corticosteroids are effective for JDM, requiring prolonged treatment duration.
- Methotrexate can be a valuable alternative for JDM patients unresponsive to steroids.